Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Juni 2026 09:00 ET | Quelle: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki...
18. Juni 2026 07:00 ET | Quelle: Essential Pharma

Essential Pharma appoints Becki Morison as Chief Executive Officer

Pharmaceutical executive brings 25+ years of international commercial leadership and rare disease experience Egham, UK – 18 June 2026 – Essential Pharma ("Essential" or "the Company"), a global...
17. Juni 2026 07:00 ET | Quelle: Exousia Pro, Inc.

NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

OTCID:MAJI announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company
15. Juni 2026 08:30 ET | Quelle: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated...
09. Juni 2026 07:00 ET | Quelle: Exousia Pro, Inc.

NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University

MAJI announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board.
08. Juni 2026 07:37 ET | Quelle: kneat.com, inc.

Kneat Enters into Definitive Agreement to be Acquired by Thoma Bravo in an All-Cash Transaction, Valuing Kneat at Approximately C$650 Million

Kneat Enters into Definitive Agreement to be Acquired by Thoma Bravo in an All-Cash Transaction, Valuing Kneat at Approximately C$650 Million
03. Juni 2026 16:30 ET | Quelle: Cellectis Inc.

Monthly information on share capital and company voting rights

PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
03. Juni 2026 16:30 ET | Quelle: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS, 03 juin 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de...
02. Juni 2026 11:23 ET | Quelle: Exousia Pro, Inc.

NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization

NexTel Medical, OTCPK: MAJI, announced the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms
01. Juni 2026 16:10 ET | Quelle: UroGen Pharma Ltd.

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today...

Nächste Seite